DECISION AIDS: THE EFFECT OF LABELING OPTIONS ON FINAL DECISIONS AND DECISION-MAKING PROCESS
Candidate for the Lee B. Lusted Student Prize Competition
Method: 523 participants recruited from an on-line survey panel completed a decision aid regarding options to prevent future cardiovascular disease. One group of panelists had a decision aid with labeled options (Aspirin and Statins), another group had blinded options (Medication A and B). Following the decision aid, participants were asked to indicate their preferred choice, confidence in their choice, and an ease-of use question. To discern the mechanism of the labeling effect, participants in blinded and labeled groups were asked to evaluate relative risks and benefits of each option.
Result: Among the group with labeld options, the odds of choosing Aspirin over Statins increased 3.8 times (coeff=1.33, P<0.000); the odds of being 1 point more confident on a 10-point scale were 30% greater (coeff=0.26, P<0.087); the odds of rating the task as 1 point easier on a 7-point scale were 79% higher (coeff=0.58, P<0.000)
When rating relative risks and benefits, those in labeled group had 45% less likelihood of rating Statin’s benefits 1 point higher (on a 9-point scale) than benefits of Aspirin compared to blinded group. The effect of labeling on evaluating risks was even larger: 71% less likelihood of favoring Statins’ risks among labeled groups compared to blinded group. Controlling for literacy, numeracy, age, gender, and education, did not change the results.
Conclusion: Even though it is natural to think that knowing the options gives people more meaningful information and enhances their decision, our study showed that people interpreted the same information on risks and benefits differently when knew the options. When decision aids include options familiar to patients it may be necessary to reveal the names of the options only after an initial blinded comparison phase.
See more of: The 36th Annual Meeting of the Society for Medical Decision Making